Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19554
Title: Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.
Authors: Bergeron, David;Gorno-Tempini, Maria L;Rabinovici, Gil D;Santos-Santos, Miguel A;Seeley, William;Miller, Bruce L;Pijnenburg, Yolande;Keulen, M Antoinette;Groot, Colin;van Berckel, Bart N M;van der Flier, Wiesje M;Scheltens, Philip;Rohrer, Jonathan D;Warren, Jason D;Schott, Jonathan M;Fox, Nick C;Sanchez-Valle, Raquel;Grau-Rivera, Oriol;Gelpi, Ellen;Seelaar, Harro;Papma, Janne M;van Swieten, John C;Hodges, John R;Leyton, Cristian E;Piguet, Olivier;Rogalsky, Emily J;Mesulam, Marsel M;Koric, Lejla;Nora, Kristensen;Pariente, Jérémie;Dickerson, Bradford;Mackenzie, Ian R;Hsiung, Ging-Yuek R;Belliard, Serge;Irwin, David J;Wolk, David A;Grossman, Murray;Jones, Matthew;Harris, Jennifer;Mann, David;Snowden, Julie S;Chrem-Mendez, Patricio;Calandri, Ismael L;Amengual, Alejandra A;Miguet-Alfonsi, Carole;Magnin, Eloi;Magnani, Giuseppe;Santangelo, Roberto;Deramecourt, Vincent;Pasquier, Florence;Mattsson, Niklas;Nilsson, Christer;Hansson, Oskar;Keith, Julia;Masellis, Mario;Black, Sandra E;Matías-Guiu, Jordi A;Cabrera-Martin, María-Nieves;Paquet, Claire;Dumuirger, Julien;Teichmann, Marc;Sarazin, Marie;Bottlaender, Michel;Dubois, Bruno;Rowe, Christopher C;Villemagne, Victor L;Vandenberghe, Rik;Granadillo, Elias;Teng, Edmond;Mendez, Mario;Meyer, Philipp T;Frings, Lars;Lleó, Alberto;Blesa, Rafael;Fortea, Juan;Seo, Sang Won;Diehl-Schmid, Janine;Grimmer, Timo;Frederiksen, Kristian Steen;Sánchez-Juan, Pascual;Chételat, Gaël;Jansen, Willemijn;Bouchard, Rémi W;Robert, Laforce;Visser, Pieter Jelle;Ossenkoppele, Rik
Affiliation: Université Laval, Faculté de Médecine, Département des Sciences Neurologiques, Quebec, QC, Canada
Université de Caen-Normandie, Inserm UMR-S U1237, Caen, France
Maastricht University, Department of Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht, Netherlands
Banner Alzheimer's Institute, Phoenix, AZ, USA
Université Laval, Clinique Interdisiplinaire de Mémoire de l'Enfant-Jésus, Quebec, QC, Canada
VU University Medical Center, Alzheimer Center, Department of Neurology, Amsterdam, Netherlands
University of California San Fransisco, Memory & Aging Center, Department of Neurology, San Fransisco, CA, USA
L'Hospitalet de Llobregat, Cognition and brain plasticity group [Bellvitge biomedical research institute- IDIBELL], Barcelona, Spain
L'Hospitalet de Llobregat, Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Barcelona, ES
VU University Medical Center, Department of Radiology and Nuclaer Medicine, Amsterdam, Netherlands
University College London, Dementia Research Centre, UCL Institute of Neurology, London, UK
Institut d'investigacions Biomèdiques August Pi i Sunyer, Alzheimer's disease and other cognitive disorders unit, Barcelona, Spain
Medical University of Vienna, Institute of Neurology, Vienna, Austria
Erasmus MC - University Medical Center, Alzheimer center, Department of Neurology, Rotterdam, Netherlands
The University of Sydney, Brain and Mind Centre, School of Medical Sciences, Sydney, Australia
The University of New South Wales, Neuroscience Research Australia and School of Medical Sciences, Sydney, Australia
Australian Research Council Centre of Excellence in Cognition and its Disorders, Sydney, Australia
Rush University, Neurological Sciences, Chicago, IL, USA
Northwestern University Medical School, Cognitive Neurology and Alzheimer Disease Center, Chicago, IL, USA
Hopital de la Timone, Service de Neurologie et de Neuropsychologie, Marseille, France
Université de Toulouse, Inserm, ToNIC, Toulouse NeuroImaging Center, Toulouse, France
Harvard Medical School, Frontotemporal Dementia Unit, Department of Neurology, Massachusetts Alzheimer's Disease Research Center, Boston, MA, USA
University of British Columbia, Division of Neurology, Department of Medicine, Vancouver, Canada
University of Pennsylvania, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA
University of Pennsylvania, Department of Neurology, Philadelphia, PA, USA
University of Pennsylvania, the Penn Frontotemporal Degeneration Center, Philadelphia, PA, USA
Greater Manchester Neurosciences Centre, Cerebral Function Unit, Manchester, UK
University of Manchester, School of Community-Based Medicine, Manchester, UK
University of Manchester, Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Manchester, UK
Neurological Research Institute (FLENI), Center of Aging and Memory, Buenos Aires, Argentina
University of Bourgogne Franche-Comté (UBFC), Regional Memory Center (CMRR), Department of Neurology, CHRU Besançon and Integrative and clinical Neurosciences Lab, Besançon, France
Vita-Salute University and IRCCS-San Raffaele Hospital, Department of Neurology, INSPE, Milan, Italy
Université Lille Nord de France, INSERM U1171, Lille, France
Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Lund, Sweden
Skåne University Hospital, Neuropsychiatric Clinic, Malmö, Sweden
Sunnybrook Health Sciences Centre, University of Toronto, Anatomical Pathology, Toronto, ON, Canada
Sunnybrook Health Sciences Centre, University of Toronto, Department of Medicine (Neurology), Toronto, ON, Canada
Sunnybrook Health Sciences Centre, University of Toronto, Hurvitz Brain Sciences Research Program, Toronto, ON, Canada
Hospital Clinico San Carlos, San Carlos Health Research Institute, Universidad Complutense, Department of Neurology and Nuclear Medicine, Madrid, Spain
Lariboisière-Fernand-Widal Hospital, Memory Center, Department of Neurology, Paris, France
Lariboisière-Fernand-Widal Hospital, Department of Pathology, Paris, France
Université Paris Descartes, Sorbonne Paris Cité, Centre Hospitalier Sainte Anne, Unit of Neurology of Memory and Language, Paris, France
Service Hospitalier Frederic Joliot, ERL 9218 CNRS, CEA, Orsay, Île-de-France, France
Universite Paris-Sud, IMIV, UMR 1023 Inserm, CEA, Orsay, Île-de-France, France
Hôpital Universitaire de la Pitié Salpêtrière, Centre des Maladies Cognitives et Comportementales, Paris, France
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Department of Medicine, Melbourne, VIC, Australia
University Hospital Leuven, Department of Neurology, Leuven, Belgium
University of California Los Angeles, Department of Neurology, Los Angeles, CA, USA
VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
University of California Los Angeles, Department of Neurology, Neurobehavior Service, Los Angeles, CA, USA
West Los Angeles VA Medical Center, Neurobehavior Unit, Los Angeles, CA, USA
University Hospital of Freiburg, Department of Nuclear Medicine, Faculty of Medicine, Freiburg, Germany
Hospital de la Santa Creu i Sant Pau, Memory Unit, Department of Neurology, Barcelona, Spain
Universitat Autónoma de Barcelona, Biomedical Research Institute Sant Pau, Barcelona, Spain
Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, Madrid, Madrid, Spain
Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Neurology, Seoul, South-Korea
Technische Universität München, Department of Psychiatry and Psychotherapy, München, Germany
Danish Dementia Research Center, Department of Neurology, Copenhagen, Denmark
Universitary Hospital Marqués de Valdecilla, Neurology Service, Santander, Spain
Issue Date: 26-Sep-2018
EDate: 2018-09-26
Citation: Annals of neurology 2018; online first: 26 September
Abstract: To estimate the prevalence of amyloid-positivity, defined by PET/CSF biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. We conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n=443], non-fluent [nfvPPA, n=333], semantic [svPPA, n=401] and mixed/unclassifiable [PPA-M/U, n=74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n=600]), PET [n=366] and/or autopsy [n=378]) available. The estimated prevalence of amyloid-positivity according to PPA variant, age and apolipoprotein E (APOE) ε4 status was determined using generalized estimating equation models. Amyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%) (p<0.001). Prevalence of amyloid-β positivity increased with age in nfvPPA (from 10% at age 50 to 27% at age 80, p<0.01) and svPPA (from 6% at age 50 to 32% at age 80, p<0.001), but not in lvPPA (p=0.94). Across PPA variants, APOE ε4 carriers were more often amyloid-β positive (58.0%) than non-carriers (35.0%, p<0.001). Autopsy data revealed Alzheimer's disease (AD) pathology as the most common pathologic diagnosis in lvPPA (76%), frontotemporal lobar degeneration - TDP-43 in svPPA (80%) and frontotemporal lobar degeneration-TDP-43/tau in nfvPPA (64%). This study shows that the current PPA classification system helps to predict underlying pathology across different cohorts and clinical settings, and suggests that age and APOE genotype should be taken into account when interpreting Aβ biomarkers in PPA patients. This article is protected by copyright. All rights reserved.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19554
DOI: 10.1002/ana.25333
ORCID: 0000-0002-1046-6408
0000-0003-3910-2453
PubMed URL: 30255971
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.